BIOVENTIX: £155k R&D Revenue And Commencement Of ‘Large-Scale Production’ Signal Increasing Alzheimer’s Success After Troponin Error Creates Below-Expectations FY 2024 And Leaves Dividend Yield Exceeding 5%

04 March 2025
By Maynard Paton

FY 2024 results summary for Bioventix (BVXP):

  • A record FY, showing revenue up 6% and profit up 5%, although the 3p per share reduction to the H2 dividend illustrated a below-expectations performance following an unfortunate troponin-royalty error.
  • Sales progress was very mixed, with best-seller vitamin D up just 1%, the now “mature” troponin up only 3%, the once-popular testosterone down 29%, 30-year-old T3 up 21% and general Chinese royalties becoming “more significant“.
  • R&D revenue of £155k, the commencement of “large-scale production“, promising snippets from scientific papers alongside ongoing Quanterix promotion suggest BVXP’s Alzheimer’s work has increasing potential to become a substantial commercial success.
  • The wonderful economics of the antibody portfolio continue, as this FY displayed a majestic 78% operating margin, a super £800k revenue per employee, net cash equivalent to a hefty 44% of revenue and capex of just £16k.
  • The £30 shares currently trade at their lowest P/E since 2016, offer a 5%-plus yield for the very first time and might value the Alzheimer’s R&D at a very pessimistic zero. I continue to hold.

Read more

[ShareScope] Screening For My Next Long-Term Winner: BIG TECHNOLOGIES

***ShareScope New Subscriber Special Offer***
Readers of my blog can claim one month of free data. Click here for details.

22 February 2025
By Maynard Paton

“It’s Probably Overpriced“

IPOs have suffered badly during the last few years.

Buoyant markets encouraged lots of companies to go public at optimistic valuations…

…only for economic conditions to turn and valuations to quickly deflate.

ShareScope lists 225 shares that joined the stock market since the start of 2020, of which 168 (75%) currently trade below their flotation price — including 66 that have lost 80% or more of their value.

But could the flotation carnage now be hiding good buying opportunities?

I have devised a new ShareScope screen to search among the IPO rubble, seeking companies that have:

  • Floated since the start of 2020;
  • A market cap of more than £50 million;
  • Net cash (i.e. net borrowings excluding IFRS 16 finance leases of less than zero);
  • A positive operating margin (i.e. are profitable);
  • Director holdings of 10% or more, and;
  • A GBP-denominated share price.
(Source: ShareScope)

ShareScope returned 11 matches, and I selected BIG Technologies because of its remarkable 51% operating margin and hefty 49% post-IPO share-price dive.

Let’s take a closer look.

Read my full BIG TECHNOLOGIES article for ShareScope >>

Maynard Paton

FW THORPE: FY 2024 Declares 22nd Consecutive Annual Dividend Increase After ‘Impressive’ Stock Procurement Improves Gross Margin To 49% While Subdued Outlook And Modest LTIP Targets Leave P/E At Lowest For 10 Years

18 February 2025
By Maynard Paton

FY 2024 results summary for FW Thorpe (TFW):

  • A 1% revenue decline was countered by a 9% profit advance, with H2 profit improving a remarkable 17% to help raise the ordinary dividend 5% and extend the run of annual payout advances to 22 years.
  • TFW’s gross margin improving to 49% through “impressive” stock procurement led to some welcome operating margins, including 20% for Thorlux, 23% for Lightronics/Famostar and 19% for Zemper’s H2, although profitability at the group’s Other subsidiaries remains poor.
  • Very satisfactory cash flow supported cash finishing £18m higher at £53m, which triggered the third special dividend in four years and almost certainly enhances the likelihood of further acquisition activity.  
  • The slimmed-down board with its M&A expertise may wish to consider the success of acquisition specialist Halma, which assesses its ‘capital allocation’ through return on total invested capital and includes the KPI as an LTIP measure.
  • The 15x P/E is the lowest rating for ten years, and seems more influenced by TFW’s subdued near-term prospects and modest LTIP targets rather than the group’s distinguished operating history and longer-term demand for energy-saving lighting. I continue to hold.

Read more

CITY OF LONDON INVESTMENT: Subdued FY 2024 Admits $320m FuM Outflow, 5-7% Client CAGRs And KPI Failure To Reinforce ‘Value Trap’ Credentials With Barely Covered Dividend Yielding 9%

29 January 2025
By Maynard Paton

FY 2024 results summary for City of London Investment (CLIG):

  • Another very subdued performance, showing revenue up 1%, profit down 1% and the annual dividend unchanged for the third consecutive FY after client withdrawals of $320m left average funds under management (FuM) just 3% higher.
  • “Constructive meetings” continue with 31.5% shareholder George Karpus, who now carries “high hopes and high expectations” for CLIG — despite the group failing to achieve its sole KPI after client-fee rates dropped 3bps while salaries climbed an average 6%.
  • Long-term client CAGRs of just 5-7% may reflect the inherent limitations of CLIG “exploiting the discount volatility” of UK investment trusts, and raises awkward comparisons to cash/bonds, the S&P 500 and sector activist Saba Capital.
  • While new clients remain elusive, plans to reduce expenses by $2.5m — albeit mostly through non-staff costs — alongside a stronger USD should help sustain this FY’s barely covered GBP dividend.
  • The subsequent H1 2025 witnessing further client withdrawals of $564m reinforces CLIG’s ‘value trap’ credentials, underlined by a share price that is back to 2007 levels and currently paying a 9% yield. I continue to hold.

Read more

[ShareScope] Small-Cap Spotlight Report: PINEWOOD TECHNOLOGIES

***ShareScope New Subscriber Special Offer***
Readers of my blog can claim one month of free data. Click here for details.

25 January 2025
By Maynard Paton

Investment ideas can emerge from the unlikeliest of sources.

I booked my car for a service the other month and the confirmation email was sent by Pinewood DMS:

DMS stands for ‘dealer management software’ and Pinewood Technologies is one of two dominant suppliers of such systems within the UK.

A DMS allows car dealers to handle all aspects of their business — such as vehicle sales, customer enquiries, workshop appointments, parts ordering, accounts processing and marketing campaigns — within a single IT package.

Pinewood was part of car dealer Pendragon for 25 years, but for the last twelve months has operated independently and now describes itself as a “pure-play SAAS business with an accelerated growth plan“.

The growth plan centres upon sophisticated IT displacing outdated competitor systems — with US dealers in particular a lucrative target.

High levels of recurring revenue earned through a ‘scalable platform’ — alongside the prospect of bumper contract wins — have meanwhile led to very attractive profit guidance.

Let’s take a closer look.

Read my full PINEWOOD TECHNOLOGIES article for ShareScope >>

Maynard Paton

Q4 2024: Up 22.4% For 2024

03 January 2025
By Maynard Paton

Happy 2025! I hope your shares prospered last year and you continue to find my blog useful.

A summary of my portfolio’s 2024:

  • Total return of +22.4%*;
  • Individual returns ranged from up 120% for System1 to down 28% for Mincon;
  • Three shares were topped-up: City of London Investment, Mountview Estates and S & U;
  • No shares were top-sliced or sold entirely, and;
  • No new shares were purchased.

(*Performance calculated using quoted bid prices and includes all dealing costs, withholding taxes, broker-account fees, paid dividends and cash interest)

I publish a portfolio review after every quarter (Q1, Q2 and Q3), and this post recaps my October/November/December activity as well as my 2024 performance.

Read more

My Portfolio: Year In Review 2024

03 January 2025
By Maynard Paton

Happy New Year!

I trust you enjoyed the festive break and are now ready to battle the market for another twelve months!

This post provides a ‘year in review’ of my current holdings. I recap how each business performed during 2024 as well as provide a few remarks about their attractions, drawbacks and valuations.

These reviews are very useful to write, not least because they help ensure I am still invested for the right reasons. I also hope the reviews help me avoid disappointing returns during the year ahead! I undertook the same review process at the start of 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023 and 2024.

My portfolio gained 22.4% during 2024 and this other post explains that performance in more detail.

Read more

TRISTEL: Record FY 2024 Discloses Impressive 32% UK Growth As Sudden US ‘Purchasing Bureaucracy’ Explains Leadership Change, Boilerplate LTIP Seeks Only 5.5% EPS CAGR And P/E Drops To Lowest Since 2018

23 December 2024
By Maynard Paton

FY 2024 results summary for Tristel (TSTL):

  • A record FY, showcasing revenue up 16%, profit up 32% and the dividend up 29%, with impressive 32% UK growth based upon 9% greater volumes and 23% higher pricing through a new NHS agreement.
  • The retirement of the previous chief executive now makes sense after “purchasing bureaucracy” suddenly beset North American progress, which left TSTL alarmingly “a year behind” schedule after US partner Parker Laboratories proved ineffective with sales.
  • The new chief executive has still to publish his financial targets, although the board has already re-committed to 5%-plus annual dividend growth while a new ‘boilerplate’ LTIP depressingly seeks only a 5.5% adjusted EPS CAGR to vest.  
  • The high-margin, cash-rich, low-tax accounts generally remain in good shape, but are let down by regular restatements alongside stagnant employee productivity that may be due to a 25% margin target limiting additional investment.
  • The trailing 25x PE is the lowest since 2018 and could be justified by further meaningful growth within established markets, the prospect one day of lucrative US royalties, the ongoing ability to raise prices and the possibility of bumper surface-disinfection sales. I continue to hold.

Read more

[ShareScope] Screening For My Next Long-Term Winner: TATTON ASSET MANAGEMENT

***ShareScope New Subscriber Special Offer***
Readers of my blog can claim one month of free data. Click here for details.

14 December 2024
By Maynard Paton

Today I have revisited a ShareScope screen that applies two ratios favoured by ‘quality’ investors — operating margin and return on equity (ROE).

The exact criteria I re-used were:

  • An operating margin (latest and 10-year average) of 20% or more, and;
  • An ROE (latest and 10-year average) of 20% or more.

Any business with a margin and ROE of at least 20% is probably quite special.

To narrow the field down further, I also sought companies that carried net cash (i.e. net borrowings excluding IFRS 16 finance leases of less than zero):

(Source: ShareScope)

This time the filter returned 17 matches, including Rightmove, Games Workshop, Cerillion, Property Franchise and six other shares I have studied for ShareScope.

I selected Tatton Asset Management because its impressive 40%-plus margin was the highest among the remaining seven names.

Let’s take a closer look.

Read my full TATTON ASSET MANAGEMENT article for ShareScope >>

SYSTEM1: New ‘Performance Culture’ Delivers FY 2024 Platform Revenue Up 43%, Record £208k Employee Productivity And Tantalising Illustrative £18m Ebitda Projection Supporting Possible £16 Share Price

30 November 2024
By Maynard Paton

FY 2024 results summary for System1 (SYS1):

  • The positive transition to data services continues, with a new “performance culture” delivering FY platform revenue up 43%, the highest reported FY profit for seven years and a reinstated annual dividend.
  • SYS1’s “unique selling proposition of predictiveness” keeps winning ad-testing clients, plaudits and attention, but remains frustratingly under-exploited for innovation testing that offers a 5x addressable market.
  • The bumper 87% gross margin, record £208k revenue per employee and near-£10m cash position were counterbalanced by one-off profit gains, mediocre bank interest and hefty bonuses obscuring margin progress.
  • The board’s true growth ambitions will be revealed through a revised LTIP, and I would trust the award-winning directors to retain the scheme’s £45m-£88m revenue range and reinstate a profit ‘underpin’.
  • A tantalising illustrative projection of revenue doubling to £60m should be very achievable given SYS1’s “3 Reasons to Believe“, and would support an adjusted Ebitda of £18m — and possible £16 share price — if the group’s margin target is met.

Read more

[SharePad] Screening For My Next Long-Term Winner: WYNNSTAY

***ShareScope New Subscriber Special Offer***
Readers of my blog can claim one month of free data. Click here for details.

08 November 2024
By Maynard Paton

I am back again looking for ‘value bargains’ and revisiting a screen that identifies companies trading at less than book value.

Importantly, this screen attempts to avoid ‘value traps’ by demanding the shares offer net cash, dividend payments and a history of trading above book value.

The exact filter criteria I redeployed were:

  • A price to net tangible assets of no more than 1;
  • A dividend being paid during the most recent year;
  • A 10-year average price to net tangible assets of at least 1;
  • Net borrowings less total leases of no more than 0 (i.e. a net cash position excluding IFRS 16 lease obligations), and;
  • A share price denominated in pounds sterling.

This time SharePad returned 13 companies:

(Source: SharePad)

I selected Wynnstay because the shares were priced at a steep discount versus their ten-year average valuation. I also liked the reassuring 20-year run of dividend payments.

Sure enough, Wynnstay’s 318p shares trade nearly 40% below the group’s 503p per share net tangible asset value:

(Source: SharePad)

My filter results indicate the shares have traded at an average 1.2x book value during the last ten years. The rating reached 2.3x during 2013, sank to 0.5x during the pandemic and languishes now at a lowly 0.6x.

Wynnstay’s net tangible assets have advanced over time, and so has the dividend. The payout has in fact been lifted every year since the group joined AIM during 2004 at 190p:

(Source: SharePad)

Given the illustrious dividend, Wynnstay does not seem the type of business that should be valued well below asset value. Yet the shares have effectively moved sideways for years; the recent 318p price was first achieved during 2011 and today supports a £73m market cap.

Let’s take a closer look.

Read my full WYNNSTAY article for SharePad >>

Maynard Paton

MOUNTVIEW ESTATES: £90 Shares Trade 12% Below NAV — Steepest Discount For More Than 10 Years — After FY 2024 Admits Third Consecutive Sub-60% Gross Margin And Re-Emphasises Subpar Gains From Post-2014 Purchases

02 November 2024
By Maynard Paton

FY 2024 results summary for Mountview Estates (MTVW):

  • A reasonable FY performance, which showed revenue up 8%, profit up 22% and the final dividend up 10% after buyers looking for “improvement potential” paid “good prices” for a more normal “profile” of properties.
  • Sales by larger landlords allowed MTVW to spend a substantial £48m on new properties, but the advance to net asset value (NAV) was just 2% after MTVW took on greater debt, paid 6%-plus interest, incurred higher tax and sold properties for £59m.
  • The absence of another formal estate valuation remains frustrating, especially given properties purchased after a 2014 valuation continue to realise subpar ‘reversionary’ gains and the overall property-sales gross margin was less than 60% for the third consecutive year.
  • The board continues to be well paid, attract 30%-plus protest votes and enjoy entrenched support through a family concert party… although not every family member seems a die-hard shareholder and recent AGM remarks even hinted MTVW could one day undertake a trade sale.
  • The £90 shares offer a 5.8% income, trade 12% below NAV — the steepest discount for at least ten years — and may be worth £182 if the group’s properties were all sold today at their vacant possession value. I continue to hold.

Read more

BIOVENTIX: Record H1 2024 Reveals Profit Up 15% Despite Slowing Troponin Growth As Encouraging Alzheimer’s Work Attracts ‘Significant Attention’ And Research-Test Availability Through Quanterix

22 October 2024
By Maynard Paton

H1 2024 results summary for Bioventix (BVXP):

  • A record H1, showing revenue up 13%, profit up 15% and the dividend up 10% as greater sales to China helped offset a “temporary” slowing of troponin growth.
  • Positive long-term progress continues to rest upon Alzheimer’s R&D, in which a study involving pTau212 suggests BVXP may enjoy a research edge beyond an increasingly crowded pTau217 field.
  • BVXP’s Alzheimer’s work on ‘brain-derived tau’ has attracted “significant attention” for helping identify significant, near-term “cognitive decline”, and is now available through Quanterix for wider research purposes.
  • The economics of successful antibodies remain superb, with this H1 displaying a terrific 77% operating margin, net cash equivalent to a hefty 40% of revenue and capex of just £5k.
  • The £37 shares yield a trailing 4.3%, trade at a possible 22x P/E and might — using some very basic assumptions — value the R&D pipeline at £23m. I continue to hold.

Read more

[SharePad] Small-Cap Spotlight Report: SOFTWARE CIRCLE

***ShareScope New Subscriber Special Offer***
Readers of my blog can claim one month of free data. Click here for details.

12 October 2024
By Maynard Paton

Mark Leonard has been described as the “best capital allocator you have never heard of“.

According to Forbes, Mr Leonard is now worth $5 billion after he established Constellation Software during 1995 and listed the group on the Toronto Stock Exchange during 2006. He then watched his shares soar more than 200-fold:

(Source: SharePad)

You may not have heard of Mr Leonard because he deliberately maintains an extremely low profile. He appears to have conducted only one public interview while pictures of him online are essentially variations of this particular image:

However, Constellation’s super stock price — currently supporting a £50 billion market cap — has gradually increased the number of investors who have heard of Mr Leonard…

…and the number of investors who have tried to replicate Constellation’s success. By 2018 Mr Leonard had seen enough copycats and decided to give up writing his annual Constellation letter. He lamented:

“For competitive reasons we are limiting the information that we disclose about our acquisition activity. We believe that sharing our tactics and best practices with a host of Constellation emulators is not in our best interest.”

Such has been the enthusiasm for how Mr Leonard created his immense wealth, a Constellation ’emulator’ has even emerged within the lower reaches of AIM.

Software Circle sports an £85 million market cap and is attempting its very own Constellation-like mega-bagger journey.

Let’s take a closer look.

Read my full SOFTWARE CIRCLE article for SharePad >>

Maynard Paton

Q3 2024: Running Multi-Baggers To 40% (Or More!) Of Your Portfolio

03 October 2024
By Maynard Paton

Happy Thursday! I trust your shares have been keeping up with this year’s rising FTSE.

A summary of my portfolio’s progress:

  • Q3 return: +7.9%*
  • Q3 trades: None.
  • YTD return: +29.4%*
  • YTD winners/losers: 3 winners vs. 7 losers.

(*Performance calculated using quoted bid prices and includes all dealing costs, withholding taxes, broker-account fees, paid dividends and cash interest)

Famous last words, but my portfolio seems on course for its best annual performance since I commenced this blog at the beginning of 2015.

As I predicted within my 2023 review, System1 has dominated my returns and what was a very large weighting has become even larger. July’s positive results from the ad-testing specialist helped push my portfolio to a record high and the question now is how far do I run this winner?

Away from System1, my portfolio’s Q3 newsflow was not perfect and some profit setbacks have started to influence my dividends.

In particular, Mincon published a terrible H1 that could not even confess its payout had been paused. As I noted in my last write-up, I can only hope the group’s family directors quickly take decisive action to revive the drill manufacturer now their €2.5m annual dividend income has ceased.

Elsewhere, S & U has admitted to further bad loans following new FCA ‘forbearance’ rules. I suspect the lender’s 17% final-dividend cut earlier this year will be followed by a similar reduction within its forthcoming H1.

Other shares not improving my income during 2024 are Andrews Sykes and City of London Investment, both of which held their latest payouts following unchanged earnings. I have also enjoyed 5%-or-less dividend increases from Mountview Estates, FW Thorpe and M Winkworth.

Only Bioventix (+10%), Tristel (+100%) and System1 (payout reintroduced) have supplied very positive dividend news during the first nine months of the year. My end-of-year returns could therefore reveal a disappointing total income.

Read more

ABOUT ME

Investing in shares for 25+ years. Former share tipster. ShareScope evangelist. Blogger. Webhost nerd. FIRE | Read more | Contact

PORTFOLIO

Holdings and buy prices. Latest trades. Quarterly updates. Annual returns from 2012. Purchases from 2004 | Read more

SHARESCOPE

The most comprehensive and best value all-in-one research and data service for private investors | Special blog offer

BLOG POST ALERTS

A simple link to every new blog post. No spam!

© maynardpaton.com 2025 • Disclaimer • Privacy • Contact